Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com
Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

April 7th 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma
Targeting GPRC5D Holds Promise in Multiple Myeloma

April 3rd 2025

Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
PROs Associated With Survival, AEs in Multiple Myeloma

April 3rd 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo